Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
PHASE3
This study is a randomized, open-label, multicenter phase III trial designe...
Status
Recruiting
Location
The Fifth Affiliated Hospital,Sun Yat-sen University
A Prospective, Exploratory Study of Becotatug Vedotin Plus Putlimab for Neoadjuvant Therapy and Adjuvant Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
PHASE2
This is a prospective, exploratory, non-registration, multi-center clinical...
Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck
PHASE2
The primary objective of this study is to compare the objective response ra...
The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study
PHASE2
This study is a four-cohort, open-label, single-center Phase II clinical tr...
Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer
PHASE2
This prospective, single-arm, exploratory multicenter clinical study aims t...